Researchers develop screening model to evaluate potential cervical cancer drugs
Oregon State University researchers have developed a screening model for rapid testing of multiple drug compounds, using a 3D cellular platform.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Oregon State University researchers have developed a screening model for rapid testing of multiple drug compounds, using a 3D cellular platform.
Spreading cancer can halt natural pathway that should recruit killer T cells directly to where it has metastasised, US scientists report.
The finding is an critical first step towards classifying lesions on the pancreas that are at highest risk of becoming cancerous, enabling their removal before they start to spread.
Results from a US study in cells and mice may have implications for the development of a new class of anticancer drugs against liver cancer.
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
Oestrogen receptors play a crucial role in breast cancer. By making them therapeutic targets, oestrogen can be regulated with the aim to prevent breast cancer.
US researchers spotlight how p53, the most frequently mutated tumour suppressor gene, can be activated against cancer cells.
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
US researchers uncover the amino acid: arginine, that prompts genetic mutations in cancer cells.
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
US researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.